Trial Profile

Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Midazolam; Yohimbine
Indications Embolism; Thrombosis
Focus Pharmacokinetics

Most Recent Events

08 Nov 2022 source (3726948)mentions The PK profles were different incomparison to historic data of 12 heathy adults who received the same FXa microdose cocktail, based on this I have added retro in design term
27 Sep 2022 Results (n=11)presented at the 2022 American College of Clinical Pharmacology Annual Meeting
27 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com